Eli Lilly and Company (LLY)

Outperform Recap: Q1 2026

Foundayo Launches, FY26 Guide Raised by $2B, Retatrutide Type-2 Diabetes Reads Through — Maintaining Outperform, FV $1,000–1,200

Outperform Recap: Q4 2025

$19.3B Quarter, Key Products +91%, FY26 Guide of $80–83B Revenue and a Pipeline That Just Doesn't Quit: Maintaining Outperform

Outperform Recap: Q3 2025

Six Phase III Orforglipron Trials Clear the Path to a 2026 Oral GLP-1 Launch, Mounjaro Internationals Accelerate, and the FY25 Guide Goes Up Again: Upgrading to Outperform

Hold Recap: Q2 2025

Tirzepatide Franchise Compounds, FY Guide Raised $1.5B at Midpoint, Orforglipron ATTAIN-1 Reads Below the Injectable Bar — Initiating LLY at Hold